Paul Weiss

1285 Avenue of the Americas
New York, NY 10019-6064
212-373-3640 (direct)
212-492-0640 (direct fax)
212-373-3000 (firm)
212-757-3990 (firm fax)


A partner in the Litigation Department, Jennifer H. Wu focuses her practice on patent litigation matters. Ms. Wu has been extensively involved in all aspects of patent litigation, including jury trials in federal district courts, trials before the International Trade Commission, and appeals to the United States Court of Appeals for the Federal Circuit and the United States Supreme Court. She has litigated patents in a wide variety of technical areas, with a particular emphasis on pharmaceuticals and biotechnology. Ms. Wu's patent litigation experience also extends to GPS devices and medical devices.Ms. Wu clerked for Judge Alan D. Lourie at the United States Court of Appeals for the Federal Circuit. She also received the Vanderbilt Medal for Service to the Law School Community and the President's Service Award for Leadership at New York University.


Her representative cases include:

  • BASF Agro B.V. et al. v. Makhteshim Agan of North America et al., No. 10-CV-276 (M.D.N.C.) (patent case involving pesticides).
  • In the Matter of Certain Light-Emitting Diodes and Prods. Containing Same, ITC Inv. No. 337-TA-785 (represented Siemens in patent case involving LED technology).
  • Pacing Technologies, LLC v. Garmin International, Inc. et al., No. 12-CV-1067 (S.D. Cal.) (patent case involving GPS devices).
  • Triangle Software, LLC v. Garmin International, Inc. et al., No. 10-CV-1457 (E.D. Va.) (obtained favorable jury verdict and district court decision in patent case involving GPS devices).
  • Genentech, Inc. v. Regeneron Pharmaceuticals, Inc. & Sanofi-Aventis U.S., Nos. 11-cv-1156; 11-cv-9463 (S.D.N.Y.) (patent cases involving products relating to Vascular Endothelial Growth Factor).
  • Cancer Research Technology Ltd. and Schering Corporation v. Barr Laboratories, No. 2010-1204 (Fed. Cir.) (obtained favorable reversal of district court judgment that rendered patent unenforceable for inequitable conduct and prosecution laches).
  • Enzo Biochem, Inc. et al. v. Applera Corp. et al., No. 2009-1281 (Fed. Cir.) (patent case involving DNA sequencing).
  • U.S. Phillips Corporation v. Iwasaki Electric Company, Ltd., No. 2009-1252 (Fed. Cir.) (patent case involving high pressure mercury vapor lamps).
  • Human Genome Sciences, Inc. v. Genentech, Inc., No. 2009-1182 (Fed. Cir.) (patent case involving interference proceedings).
  • Medicis Pharmaceutical Corp. v. Mylan Inc., Ranbaxy Inc., Sandoz, Inc., Barr Laboratories, Inc., Aurobindo Pharma, Ltd., et al., Nos. 09-CV-00033, 10-CV-00120, 10-CV-524, 10-CV-01050 (D. Del.) (patent cases involving acne drug).
  • Medicis Pharmaceutical Corp. v. Lupin Ltd., Barr Laboratories, Inc. et al., Nos. 09-CV-03062, 09-CV-03464 (D. Md.) (patent cases involving acne drug).
  • Impax Laboratories, Inc. v. Medicis Pharmaceutical Corp., No. 08-CV-00253 (N.D. Cal.) (obtained favorable dismissal of declaratory judgment action seeking to invalidate patent).
  • Prasco, LLC v. Medicis Pharmaceutical Corp. et al., No. 2007-1524 (Fed. Cir.) (obtained favorable affirmance of district court judgment dismissing case for lack of declaratory judgment jurisdiction).
  • PDL Biopharma Inc. v. Alexion Pharmaceuticals Inc., No. 07-CV-00156 (D. Del.) (patent case involving humanized antibodies).
  • Apple Computer Inc. v., Inc., No. 06-CV-00019 (N.D. Cal.) (obtained favorable summary judgment decision of invalidity).
  • Storage Technology v. Cisco Systems, Inc., No. 00-CV-01176 (N.D. Cal.) (obtained favorable jury verdict of noninfringement and invalidity).
  • Genetic Technologies Ltd. v. Applera Corp., No. 03-CV-01316 (N.D. Cal.) (patent case involving DNA sequencing).



  • J.D., New York University School of Law
    cum laude 
  • A.B., Harvard University
    cum laude 


  • Hon. Alan D. Lourie, U.S. Court of Appeals, Federal Circuit

Bar Admissions

  • New York
  • New Jersey

See Library Tab for articles, publications and presentations by Jennifer Wu

Thank you for your interest in Lawdragon.